Join the Parkinson's Disease group to help and get support from people like you.
Parkinson's Disease News (Page 4)
Related terms: Parkinson's
Acadia Pharmaceuticals Announces FDA Approval of New Dosing Formulation and Strength for Nuplazid (pimavanserin)
SAN DIEGO--(BUSINESS WIRE)--Jun. 29, 2018-- Acadia Pharmaceuticals Inc. today announced FDA approval of a new capsule dose formulation and a new tablet strength of Nuplazid (pimavanserin) to help in...
FDA Approves Osmolex ER (amantadine) for the treatment of Parkinson’s Disease and Drug-Induced Extrapyramidal Reactions
BRIDGEWATER, N.J., Feb. 19, 2018 (GLOBE NEWSWIRE) – Osmotica Pharmaceutical US LLC (“Osmotica” or the “Company”), a privately-held specialty pharmaceutical company developing novel central nervous sy...
FDA Approves Xadago (safinamide) as an Add-On Treatment for Patients with Parkinson’s Disease
March 21, 2017 – The U.S. Food and Drug Administration today approved Xadago (safinamide) tablets as an add-on treatment for patients with Parkinson’s disease who are currently taking l...
FDA Approves Nuplazid (pimavanserin) for Parkinson’s Disease Psychosis
April 29, 2016 – The U.S. Food and Drug Administration today approved Nuplazid (pimavanserin) tablets, the first drug approved to treat hallucinations and delusions associated with psychosis...
FDA Medwatch Alert: Entacapone: Drug Safety Communication - FDA Review Found No Increased Cardiovascular Risks
Including Comtan (entacapone) and Stalevo (entacapone, carbidopa, and levodopa) ISSUE: An FDA safety review has found no clear evidence of an increased risk of heart attacks, stroke, or other...
FDA Approves Duopa (carbidopa and levodopa) Enteral Suspension for Parkinson's Disease
NORTH CHICAGO, Ill., Jan. 12, 2015 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) has approved AbbVie's (NYSE: ABBV) Duopa (carbidopa and levodopa) enteral suspension for the treatment...
Impax Pharmaceuticals Announce FDA Approval of Rytary (carbidopa and levodopa) for Parkinson's Disease
HAYWARD, Calif., Jan. 8, 2015 /PRNewswire/ – Impax Pharmaceuticals, a division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced that the U.S. Food and Drug Administration (FDA) approved...
FDA Medwatch Alert: Benztropine Mesylate Injection (Nexus Pharmaceuticals): Recall - Visible Particulate Matter
ISSUE: Nexus Pharmaceuticals Inc. is recalling two lots of Benztropine Mesylate Injection, USP, 2 mg/2mL (1mg/mL) in 2 mL single dose vials due to the presence of visible particulate matter in the...
FDA Medwatch Alert: Benztropine Mesylate Injection by Fresenius Kabi USA: Recall - Potential Presence Of Glass Particles
ISSUE: Fresenius Kabi USA is voluntarily recalling four lots of Benztropine Mesylate Injection, USP, 2 mg/2mL (1mg/mL) in 2 mL single dose vials due to the potential presence of glass particles...
FDA Medwatch Alert: Mirapex (pramipexole): Drug Safety Communication - Ongoing Safety Review, Possible Risk of Heart Failure
ISSUE: FDA notified healthcare profesionals about a possible increased risk of heart failure with Mirapex (pramipexole). Results of recent studies suggest a potential risk of heart failure that needs...
Higher Dose of Novartis Drug Exelon Patch Approved By FDA for Patients With Mild to Moderate Alzheimer's Disease
EAST HANOVER, N.J., Sept. 4, 2012 /PRNewswire/ – The US Food and Drug Administration has approved a higher dose of Exelon Patch (rivastigmine transdermal system) for the treatment of people with...
Once-Daily Mirapex ER Now Approved by FDA for Both Early and Advanced Parkinson's Disease
RIDGEFIELD, Conn., March 23 /PRNewswire/ – Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily Mirapex ER...
FDA Approves Once-Daily Mirapex ER for the Treatment of Early Parkinson's Disease
RIDGEFIELD, Conn., Feb. 22 /PRNewswire/ – Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Mirapex ER (pramipexole...
FDA Approves Newly Revised Prescribing Information for Azilect Reducing Medication and Food Restrictions
JERUSALEM--(BUSINESS WIRE)--Dec 14, 2009 - Teva Pharmaceutical Industries, Ltd. today announced the U.S. Food and Drug Administration (FDA) approved the newly revised prescribing information for...
Ask a question
To post your own question to this support group, sign in or create an account.